Literature DB >> 28149656

Immune and inflammatory gene expressions are different in Behçet's disease compared to those in Familial Mediterranean Fever.

Filiz Türe Özdemir1, Emel Ekşioğlu Demiralp2, Sibel Z Aydın3, Pamir Atagündüz4, Tülin Ergun5, Haner Direskeneli4.   

Abstract

OBJECTIVE: The immune classification of Behçet's disease (BD) is still controversial. In this study, we aimed to compare the immune/inflammatory gene expressions in BD with those in familial Mediterranean fever (FMF), an autoinflammatory disorder with innate immune activation.
MATERIAL AND METHODS: CD4+ T cells and CD14+ monocytes were isolated from the peripheral blood mononuclear cells of Behçet's disease patients (n=10), FMF (n=6) patients, and healthy controls (n=4) with microbeads, and then, the mRNA was isolated. The expressions of 440 genes associated with immune and inflammatory responses were studied with a focused DNA microarray using a chemiluminescent tagging system. Changes above 1.5-fold and below 0.8-fold were accepted to be significant.
RESULTS: In BD patients, in the CD4+ T-lymphocyte subset, interleukin 18 receptor accessory protein (1.7-fold), IL-7 receptor (1.9-fold), and prokineticin 2 (2.5-fold) were all increased compared to those in FMF patients, whereas chemokine (C-X3-C motif ) receptor-1 (CX3CR1) (0.7-fold) and endothelial cell growth factor-1 (0.6-fold) were decreased. In the CD14+ monocyte population, the V-fos FBJ murine osteosarcoma viral oncogene homolog (1.5-fold), Interleukin-8 (IL-8) (2.1-fold), and Tumor Necrosis Factor alpha (TNF-α) (1.8-fold) were all increased, whereas the chemokine (C-C motif ) ligand 5 (CCL5) (0.6-fold), C-C chemokine receptor type 7 (0.6-fold), and CX3CR1 (0.7-fold) were decreased, again when compared to those in FMF. Compared to healthy controls in the CD4+ T-lymphocyte population, in both BD and FMF patients, pro-platelet basic protein and CD27 had elevated expression. In BD and FMF patients, 24 and 19 genes, respectively, were downregulated, with 15 overlapping genes between both disorders. In the CD14+ monocytes population, chemokine (C-C motif ) receptor-1 (CCR1) was upregulated both in BD and FMF patients compared to that in the controls, whereas CCL5 was downregulated.
CONCLUSION: Immune and inflammatory gene expressions seem to be variable in both the innate (CD14+) and adaptive (CD4+) immune responses in BD and FMF patients compared to those in controls, suggesting differences in immune regulation between the two disorders.

Entities:  

Keywords:  Behçet’s disease; familial Mediterranean fever; gene expression

Year:  2016        PMID: 28149656      PMCID: PMC5283560          DOI: 10.5152/eurjrheum.2016.15099

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  28 in total

Review 1.  Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?

Authors:  H Direskeneli
Journal:  Rheumatology (Oxford)       Date:  2006-09-23       Impact factor: 7.580

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations?

Authors:  U Musabak; S Pay; H Erdem; I Simsek; A Pekel; A Dinc; A Sengul
Journal:  Rheumatol Int       Date:  2005-10-05       Impact factor: 2.631

Review 4.  Familial autoinflammatory diseases: genetics, pathogenesis and treatment.

Authors:  Silvia Stojanov; Daniel L Kastner
Journal:  Curr Opin Rheumatol       Date:  2005-09       Impact factor: 5.006

5.  The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain.

Authors:  Elisa Giannini; Roberta Lattanzi; Annalisa Nicotra; Antonio F Campese; Paola Grazioli; Isabella Screpanti; Gianfranco Balboni; Severo Salvadori; Paola Sacerdote; Lucia Negri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

Review 6.  Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

Authors:  Aikaterini Arida; Kalliopi Fragiadaki; Eirini Giavri; Petros P Sfikakis
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

7.  Oligoclonal T cell expansions in patients with Behçet's disease.

Authors:  H Direskeneli; E Eksioglu-Demiralp; A Kibaroglu; S Yavuz; T Ergun; T Akoglu
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

8.  Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease.

Authors:  M Ben Ahmed; H Houman; M Miled; K Dellagi; H Louzir
Journal:  Arthritis Rheum       Date:  2004-07

9.  A CD8+ T cell transcription signature predicts prognosis in autoimmune disease.

Authors:  Eoin F McKinney; Paul A Lyons; Edward J Carr; Jane L Hollis; David R W Jayne; Lisa C Willcocks; Maria Koukoulaki; Alvis Brazma; Vojislav Jovanovic; D Michael Kemeny; Andrew J Pollard; Paul A Macary; Afzal N Chaudhry; Kenneth G C Smith
Journal:  Nat Med       Date:  2010-04-18       Impact factor: 53.440

Review 10.  Microarray analysis of gene expression in lupus.

Authors:  Mary K Crow; Jay Wohlgemuth
Journal:  Arthritis Res Ther       Date:  2003-10-13       Impact factor: 5.156

View more
  1 in total

1.  Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-Behçet's Disease.

Authors:  Elif Ugurel; Ece Erdag; Cem Ismail Kucukali; Ayca Olcay; Elif Sanli; Ece Akbayir; Murat Kurtuncu; Tuncay Gunduz; Vuslat Yilmaz; Erdem Tuzun; Burcak Vural
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.